Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

B. Dahlof; R.B. Devereau; S.E. Kjeldsen; S. Julius; Dennis Johnston

Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

B. Dahlof, R.B. Devereau, S.E. Kjeldsen, S. Julius, Dennis Johnston

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	995-1003
Number of pages	9
Journal	The Lancet
Volume	359
Issue number	9311
Publication status	Published - 23 Mar 2002

ASJC Scopus subject areas

General Medicine

Cite this

@article{76d191fc59374c4fa2bfe96278d713b1,

title = "Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol",

author = "B. Dahlof and R.B. Devereau and S.E. Kjeldsen and S. Julius and Dennis Johnston",

year = "2002",

month = mar,

day = "23",

language = "English",

volume = "359",

pages = "995--1003",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "9311",

}

TY - JOUR

T1 - Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

AU - Dahlof, B.

AU - Devereau, R.B.

AU - Kjeldsen, S.E.

AU - Julius, S.

AU - Johnston, Dennis

PY - 2002/3/23

Y1 - 2002/3/23

UR - http://www.scopus.com/inward/record.url?scp=0037160968&partnerID=8YFLogxK

M3 - Article

SN - 0140-6736

VL - 359

SP - 995

EP - 1003

JO - The Lancet

JF - The Lancet

IS - 9311

ER -

Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

ASJC Scopus subject areas

Other files and links

Cite this